No strategy for pregnant women with glaucoma

Article

The results of a questionnaire sent out to consultant ophthalmologists in the UK, has discovered that there is no one strategy in place for the management of glaucoma in pregnant women.

The results of a questionnaire sent out to consultant ophthalmologists in the UK, has discovered that there is no one strategy in place for the management of glaucoma in pregnant women.

Daniela Vaideanu and Scott Fraser from the Sunderland Eye Infirmary, Tyne and Wear, UK sent out a questionnaire to all consultant ophthalmologists in the UK asking whether they had previous experience of treating pregnant women with glaucoma. If the respondents replied that they had, they were also asked what management they had used, what management they would currently employ and, if they were to use medical treatment, what would be their first choice agent.

Of the 605 questionnaires sent out, 282 were returned. Of the respondents, 26% had previously treated pregnant women with glaucoma. Most (71%) had continued with the therapy that the women were already on. In total, 34%, on observing the situation, decided not to treat. When asked what they would currently do in this scenario, 31% responded that they were unsure and 40% replied that they would continue the current treatment. A total of 45% of respondents said that they would use beta-blockers, should medical treatment be required, whereas 33% said they would use prostaglandins.

On review of the data, the researchers concluded that, although more than a quarter of ophthalmologists have come across the situation, there is currently no optimal strategy in place for dealing with it. They suggest that guidelines be produced based on current knowledge and modified as new evidence appears.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.